Absci Corp (ABSI): Revenue

Annual figures by period end, from SEC filings.

$2.80M
Year ended 2025-12-31
$1.56M
Trailing 12 months to 2026-06-30
-14.8%
3-year compound annual growth
-7.4%
5-year compound annual growth
$5.72M2020-12-31: $4.12M2021-12-31: $4.01M2022-12-31: $4.53M2023-12-31: $5.72M2024-12-31: $4.53M2025-12-31: $2.80M$2.80M
2020-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$2.80M-38.2%2026-03-24, From 2025-01-01
2024-12-31$4.53M-20.7%2026-03-24, From 2024-01-01
2023-12-31$5.72M+26.3%2025-03-18, From 2023-01-01
2022-12-31$4.53M+13.0%2024-03-21, From 2022-01-01
2021-12-31$4.01M-2.6%2023-03-30, From 2021-01-01
2020-12-31$4.12Mn/a2022-03-22, From 2020-01-01

Revenue at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Absci Corp (ABSI)2025-12-31$2.80M-38.2%
iSpecimen Inc. (ISPC)2025-12-31$1.93M-79.2%
OneMedNet Corp (ONMD)2025-12-31$1.36M+111.4%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$6.16M-34.2%
Foxo Technologies Inc. (FOXO)2025-12-31$16.37M+304.0%
OmniAb, Inc. (OABI)2025-12-31$18.67M-29.3%
Cannabis Bioscience International Holdings, Inc. (CBIH)2025-05-31$303.0K+21.8%
MaxCyte, Inc. (MXCT)2025-12-31$33.03M-14.5%
NRC Health (NRC)2025-12-31$137.39M-4.0%

Compare ABSI, ISPC, ONMD, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗